“Feasibility” Counts at FDA: Different Approach in Antibiotics
This article was originally published in RPM Report
Venture capitalists and other investors in drug development often howl about FDA policy changes that they view as crippling innovation in certain classes. They may not think FDA listens, but clearly the agency does. FDA just doesn’t always agree.